dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· June 11, 2026

Adobe Reports Record Q2 Results

View original at finance.yahoo.com
Adobe Reports Record Q2 Results Adobe Raises FY26 Total Revenue and Non-GAAP EPS Targets AI-first ARR triples year over year and exceeds $500 million SAN JOSE, Calif., June 11, 2026--(BUSINESS WIRE)--Adobe (Nasdaq:ADBE), the global technology leader that unleashes creativity and productivity for individuals and busines…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Adobe is bringing AI products to consumers, business professionals, creators, and marketers to deliver on its mission to Empower Everyone to Create.

    60% confidence

  • FY26 financial targets factor in the acquisition of Semrush Holdings, Inc. and assume current macroeconomic conditions.

    60% confidence

  • Q2 FY2026 GAAP results reflect a $0.17 per share non-cash goodwill impairment charge related to the Publishing & Advertising reporting unit.

    60% confidence

  • AI-first ARR tripled year over year and exceeded $500 million.

    60% confidence

  • Adobe delivered record revenue of $6.62 billion in Q2 reflecting strong AI-driven demand across customer groups and is raising full-year fiscal 2026 revenue and non-GAAP EPS targets.

    60% confidence

Data points we hold from this source

Adobe Inc. · backlog27.10 USD
Adobe Inc. · margin2.24 USD
Adobe Inc. · eps4.25 USD
Adobe Inc. · cash2.17 USD
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,995
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,995 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Adobe Reports Record Q2 Results: Source | Via News | fr.via.news